United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.59 USD
-5.15 (-1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $331.56 -0.03 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 561 - 580 ( 598 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2Q11 Results Review: Tyvaso and Adcirca Ramp; FREEDOMC2 Results on Track for Late August Read Out
Provider: AURIGA USA
Analyst: MCDONALD P
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Beat With Strong Product Sales. We Believe UTHR Is At An Attractive Valuation
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
FREEDOM-M Results Are Good, But Fall Short of High Expectations; Still an Effective Agent
Provider: AURIGA USA
Analyst: MCDONALD P
Company: United Therapeutics Corporation
Industry: Medical - Drugs
We Believe FREEDOM-m Results Are More Positive Than At First Glance.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Preview of UTHR Presentations at the American Thoracic Society (ATS) International Conference.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
We are assuming coverage with a Buy rating and a $90 price target
Provider: AURIGA USA
Analyst: MCDONALD P
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Missed But Growth Intact and We See Significant Upside From Near-Term Data. Raising Rating to OUTPERFORM from NEUTRAL and FV to $94 from $79
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
FREEDOM-C2 Trial Enrolled with Data Anticipated in September
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Financials Missed But Not Material in our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Preview: We Believe Q4 Consensus Is a Bit High; However, Since UTHR Is Trading In-Line, We Anticipate a Small Miss Won''t Be Material. Raising FV to $77 from 72
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2011 Major Value Drivers in Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L